Research/art/teacher profile of a person
Name and surname:
doc. MUDr. Katarína Rejleková, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Rejleková
I.2 - Name
Katarína
I.3 - Degrees
Assoc. Prof. MD. PhD.
I.4 - Year of birth
1978
I.5 - Name of the workplace
2nd Department of Oncology
I.6 - Address of the workplace
Klenová 1, 83310, Bratislava
I.7 - Position
Academic Scientific Researcher
I.8 - E-mail address
k.rejlekova@gmail.com
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/3481
I.10 - Name of the study field in which a person works at the university
Oncology
I.11 - ORCID iD
0000-0002-2142-3411

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2005
II.c - Study field and programme
General Medicine
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2005
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2009
II.c - Study field and programme
Oncology
II.4 - Associate professor
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2023
II.c - Study field and programme
Oncology
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Academic Scientific Researcher Comenius University in Bratislava, Faculty of Medicine 2024 - current
Academic Deputy National Cancer Institute, Bratislava 2023 - 2024
Assistant Professor Comenius University in Bratislava, Faculty of Medicine 2009 - 2024
Medical Oncologist National Cancer Institute, Bratislava 2014 - current
Medical Fellow National Cancer Institute, Bratislava 2005 - 2014

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Board Certification Clinical Oncology Comenius University in Bratislava, Faculty of Medicine 2014
Certificate IV in Business Administration Central College Sydney, Australia 2002
IRIS International Research Interdisciplinary School 2024
Team-Based Learning Course Faculty of Medicine Comenius University 2024

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Socially significant malignancies General Medicine I.+II. General Medicine
Oncology
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
1
V.4.c - Dissertation (third degree)
1
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
6
V.4.c - Dissertation (third degree)
oponent
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Socially Significant Malignancies General Medicine I.+II. General Medicine

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
100
VI.1.b - Over the last six years
60
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
48
VI.1.b - Over the last six years
36
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
614
VI.1.b - Over the last six years
425
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
419
VI.1.b - Over the last six years
361
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
40
VI.1.b - Over the last six years
30
VI.2 - The most significant research/artistic/other outputs
1

Rejleková Katarína. Severe complications in patients with germ cell tumors. ISBN 978-80-223-5466-0. 2022

2

Rejlekova Katarina, Katarina Kalavska, Marek Makovnik, Nikola Hapakova, Michal Chovanec, Valentina De Angelis, Jana Obertova, Patrik Palacka, Zuzana Sycova-Mila, Jozef Mardiak and Michal Mego. Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors. Frontiers in Oncology. 2022

3

Rejlekova Katarina, Maria C Cursano, Ugo De Giorgi, and Michal Mego. Severe complications in testicular germ cell tumors: the choriocarcinoma syndrome. Frontiers in Endocrinology. 2019

4

Mego Michal, Rejlekova Katarina, Svetlovska Daniela, Miskovska Vera, Gillis AJM, De Angelis Valentina, Kalavska Katarina, Jana Obertova, Patrik Palacka , Maria Reckova, Zuzana Sycova-Mila, Daniel Pindak, Michal Chovanec, Leendert H J Looijenga , Jozef Mardiak. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial. Eur Urol Open Sci. 2021

5

Rejlekova K, M Mego, Z Sycova-Mila, J Obertova, J Rajec, T Salek, and J Mardiak. Prognostic factors in patients with relapsed or primary refractory germ cell tumors. Neoplasma. 2009

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Rejleková Katarína. Severe complications in patients with germ cell tumors. ISBN 978-80-223-5466-0. 2022

2

Rejlekova Katarina, Katarina Kalavska, Marek Makovnik, Nikola Hapakova, Michal Chovanec, Valentina De Angelis, Jana Obertova, Patrik Palacka, Zuzana Sycova-Mila, Jozef Mardiak and Michal Mego. Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors. Frontiers in Oncology. 2022

3

Rejlekova Katarina, Maria C Cursano, Ugo De Giorgi, and Michal Mego. Severe complications in testicular germ cell tumors: the choriocarcinoma syndrome. Frontiers in Endocrinology. 2019

4

Mego Michal, Rejlekova Katarina, Svetlovska Daniela, Miskovska Vera, Gillis AJM, De Angelis Valentina, Kalavska Katarina, Jana Obertova, Patrik Palacka , Maria Reckova, Zuzana Sycova-Mila, Daniel Pindak, Michal Chovanec, Leendert H J Looijenga , Jozef Mardiak. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial. Eur Urol Open Sci. 2021

5

Peter Lesko, Jana Obertova, Karol Kajo, Katarina Rejlekova, Zuzana Orszaghova, Viera Lehotska, Martina Ondrusova, Michal Chovanec, Dalibor Ondrus, Michal Mego. Testicular Seminoma in Prostate: Case Report and Review of Literature. Clinical Genitourinary Cancer. 2023

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Rejlekova Katarina, Maria C Cursano, Ugo De Giorgi, and Michal Mego. Severe complications in testicular germ cell tumors: the choriocarcinoma syndrome. Frontiers in Endocrinology. 2019


Citation: Müller, M.R., Burmeister, A., Skowron, M.A. et al. Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. Clin Epigenet. 2022

2

Z Cierna, M Mego, V Miskovska, K Machalekova, M Chovanec, D Svetlovska, K Hainova, K Rejlekova, D Macak, S Spanik, D Ondrus, K Kajo, J Mardiak, P Babal. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Annals of oncology. 2016


Citiation: N. Adra, L.H. Einhorn, S.K. Althouse, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Annals of Oncology. 2018

3

Michal Chovanec, Zuzana Cierna, Viera Miskovska, Katarina Machalekova, Katarina Kalavska, Katarina Rejlekova, Daniela Svetlovska, Dusan Macak, Stanislav Spanik, Karol Kajo, Pavel Babal, Ugo De Giorgi, Michal Mego, Jozef Mardiak. Systemic immune-inflammation index in germ-cell tumours. British journal of cancer. 2018


Citation: Gabriela Trifan, Fernando D. Testai. Systemic Immune-Inflammation (SII) index predicts poor outcome after spontaneous supratentorial intracerebral hemorrhage. Journal of Stroke and Cerebrovascular Diseases. 2020

4

Michal Chovanec, Zuzana Cierna, Viera Miskovska, Katarina Machalekova, Daniela Svetlovska, Katarina Kalavska, Katarina Rejlekova, Stanislav Spanik, Karol Kajo, Pavel Babal, Jozef Mardiak, Michal Mego. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget. 2017

 

Citation: Chovanec, Michal, et al. Systemic immune-inflammation index in germ-cell tumours. British journal of cancer. 2018

5

Michal Mego, Daniela Svetlovska, Vera Miskovska, Jana Obertova, Patrik Palacka, Jan Rajec, Zuzana Sycova-Mila, Michal Chovanec, Katarina Rejlekova, Peter Zuzák, Dalibor Ondrus, Stanislav Spanik, Maria Reckova, Jozef Mardiak. Phase II study of everolimus in refractory testicular germ cell tumors. Urologic Oncology. 2016

 

Citation: de Vries, Gerda, et al. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treatment Reviews. 2020

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

R2 - Fellowship for Excellent Researcher- 09I03-03-V04-00189-Predictive biomarkers of lung damage of bleomycin toxicity- Principal Investigator

2

APVV-20-0158- Identifikácia nových terapeutických možností pri refraktérnych nádoroch z germinatívnych buniek- Sub-Investigator

3

APVV-19-0411- Identifikácia a validácia biomarkerov a zodpovedných molekulárnych dráh neskorej toxicity kuratívnej liečby u germinatívnych nádorov-Sub-Investigator

4

VEGA 1/0327/19-Identifikácia úlohy mikrobiómu a imunitných molekulárnych mechanizmov kognitínych dysfunkcií následkom neskorej toxicity-Sub-Investigator

5

MZ SR 2018/39-LFUK-13-Prekonanie rezistencie voči cisplatine u refraktérnych testikulárnych nádorov zo zárodočných buniek prostredníctvom terapie nasmerovanej voči markerom nádorových kmeňových buniek- Sub-Investigator

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Supervising and reviewing of specialization theses Comenius University in Bratislava, Faculty of Medicine 2015 - current
Supervising and reviewing of diploma theses Comenius University in Bratislava, Faculty of Medicine 2015 - current
Supervising and reviewing of PhD theses Comenius University in Bratislava, Faculty of Medicine 2021 - current

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
University of Pittsburgh 4200 5th Ave, Pittsburgh, PA 15260, USA 2021- 6 months RCM Fellowship, Research scholar with academic appointment, GU Malignancies Department
Memorial Sloan Kettering Cancer Center, New York 1275 York Avenue, New York, NY, 10065, USA 2019-3 months UICC ICRETT Fellowship, GU Malignances Department, Observer
Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico Calle Hospital 278, 44200 Guadalajara, Jalisco, Mexico 2004- 2 months ERASMUS Traineeship, Oncology Department, Observer
Jackson Memorial Hospital, Miami 1611 NW 12th Ave, Miami, FL 33136, USA 2000- 2 months Internal Medicine Department, Observer
Masaryk Memorial Cancer Institute Brno, Czech republic 2024- 2 weeks SAIA Academic Research Stay

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

2024 - current: Editorial Board Member - Klinická onkologie

2023- current: European Organisation for Research and Treatment of Cancer (EORTC)- work group for genitourinary malignancies, quality of life

2022 - current: Associate Editor - Clinical Genitourinary Cancer, Elsevier, USA

2022 - current: Investigator - MaGIC, Malignant Germ Cell International Consortium

2022 - current: Deputy Chairman - Geriatric Section of the Slovak Oncology Society (SOS)

Membership: American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Slovak Medical Society, Slovak Oncology Society (SOS), Slovak Medical Association

Date of last update
2025-04-11